Q4 2023 13F Holders as of 31 Dec 2023
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
95,963,102
-
Number of holders
-
236
-
Total 13F shares, excl. options
-
80,397,353
-
Shares change
-
+10,299,160
-
Total reported value, excl. options
-
$3,844,802,509
-
Value change
-
+$498,492,380
-
Put/Call ratio
-
115%
-
Number of buys
-
133
-
Number of sells
-
-96
-
Price
-
$47.82
Significant Holders of Ultragenyx Pharmaceutical Inc. - COMMON STOCK (RARE) as of Q4 2023
278 filings reported holding RARE - Ultragenyx Pharmaceutical Inc. - COMMON STOCK as of Q4 2023.
Ultragenyx Pharmaceutical Inc. - COMMON STOCK (RARE) has 236 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 80,397,353 shares
of 95,963,102 outstanding shares and own 84% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (8,673,432 shares), RTW INVESTMENTS, LP (6,887,086 shares), BlackRock Inc. (5,238,400 shares), WELLINGTON MANAGEMENT GROUP LLP (4,415,029 shares), SANDS CAPITAL MANAGEMENT, LLC (4,118,008 shares), PRICE T ROWE ASSOCIATES INC /MD/ (3,448,698 shares), STATE STREET CORP (3,252,502 shares), FEDERATED HERMES, INC. (2,446,500 shares), Clearbridge Investments, LLC (2,383,492 shares), and ALKEON CAPITAL MANAGEMENT LLC (2,241,832 shares).
This table shows the top 236 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.